SAT0234

TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 9 YEARS

J. Wollenhaupt¹, J. Silverfield², E. B. Lee³, K. Terry⁴, K. Kwok⁵, S. Strengholt⁶, R. DeMasi⁷, L. Wang⁸. ¹Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, United States, ³Seoul National University, Seoul, Korea, Republic Of, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, United States, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer Inc, Collegeville, PA, United States

Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).

Objectives: To report tofacitinib safety and tolerability up to 114 months and clinical efficacy up to 96 months in long-term extension (LTE) studies.

Methods: Data were pooled from 2 open-label studies (NCT00413699 [database locked as of March 2017]; and NCT00661661) of patients with RA who had participated in qualifying Phase 1/2/3 studies of tofacitinib. Patients received tofacitinib 5 or 10 mg twice daily (BID) as monotherapy or with background conventional synthetic (cs)DMARDs. As patients in the LTE studies were allowed to switch doses, they were assigned to the 5 mg BID group if the total daily dose (TDD) was <15 mg/day, and to the 10 mg BID group if TDD was ≥15 mg/day. Primary endpoints were adverse events (AEs) and confirmed laboratory safety data. Other endpoints included clinical efficacy measures (ACR20/50/70 response rates, mean DAS28-4[ESR] score, mean HAQ-DI score and mean change from baseline in Clinical Disease Activity Index score). Safety data were included up to Month 114 and completer-analyzed efficacy data up to Month 96 (n≤100 post-Month 96).

Table 1 Safety data (Month 114) and clinical efficacy outcomes (up to Month 96; as observed) in LTE studies of tofacitinib in patients with RA

Tofacitinib (5 and 10 mg BID) ± background csDMARDs N=4967			
AEs of interest	IR per 100 py (95% CI)		
Serious adverse events	9.13 (8.67, 9.61)		
Serious infections	2.46 (2.23, 2.70)		
Malignancies (excluding NMSC)	0.83 (0.71, 0.98)		
Confirmed laboratory abnormalities	n (%)	IR per 100 py (95% CI)	
Decrease from baseline in hemoglobin ≥3 g/dL or hemoglobin ≤7 g/dL	104 (2.1)	0.59 (0.48, 0.71)	
Neutropenia, ANC <0.5 × 10 ⁹ /mm ³	0 (0.0)	0 (0.0, 0.0)	
Lymphopenia, ALC <0.5 × 10 ⁹ /mm ³	70 (1.4)	0.39 (0.30, 0.49)	
Aminotransferases			
ALT >3 × ULN	285 (5.7)	1.62 (1.44, 1.82)	
AST >3 × ULN	166 (3.3)	0.93 (0.79, 1.08)	
Serum creatinine increase >50% from baseline	138 (2.8)	0.77 (0.65, 0.91)	
Clinical efficacy outcomes	Baseline	Month 1	Month 96
ACR response rates, %	N=4907	N=163	N=163
ACR20	NA	73.7	77.9
ACR50	NA	49.9	59.5
ACR70	NA	29.2	41.7
DAS28-4(ESR) score, mean (SE)	N=4782	N=4776	N=161
	6.32 (0.01)	3.75 (0.02)	3.34 (0.09)
HAQ-DI score, mean (SE)	N=4924	N=4880	N=163
	1.42 (0.01)	0.82 (0.01)	0.77 (0.05)
CDAI score, mean change from baseline (SE)	NA	N=4802	N=161
		-24.5 (0.21)	-30.7 (1.05)

ACR20/50/70, American College of Rheumatology 20%/50%/70% improvement; AE, adverse event; ALC, absolute lymphocyte count; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BID, twice daily; CDAI, Clinical Disease Activity Index; CI, confidence interval; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28-4(ESR), Disease Activity Score in 28 joints; erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; IR, incidence rate; LTE, long-term extension; N, number of evaluable patients; NA, not applicable; NMSC, non-melanoma skin cancer; py, patient-years; RA, rheumatoid arthritis; SE, standard error; ULN, upper limit of normal

Results: Overall, 4967 patients were treated (mean [max] duration: 3.5 [9.4] years). Total tofacitinib exposure was 17,738.5 patient-years (py); 76.4% of patients maintained their initial dose. In total, 2518 patients (50.7%) discontinued (AEs: 1189 [23.9%]; insufficient clinical response: 179 [3.6%]). The most common classes of AE were infections and infestations (69.6%; exposure adjusted event rate [EAER; events per 100 py], 19.71) and musculoskeletal/connective tissue disorders (40.3%; EAER, 11.40). The most common AEs were nasopharyngitis (19.1%; EAER, 5.41), upper respiratory tract infection (17.9%; EAER, 5.07), bronchitis (12.6%; EAER, 3.58) and urinary tract infection (12.5%; EAER, 3.55). Serious AEs occurred in 29.4% of patients and serious infections (SIEs) in 8.9% of patients. Malignancies, excluding non-melanoma skin cancer, were reported in 3.0% of patients. Incidence rates (IR; patients with events per 100 py) for AEs of interest, with 95% confidence intervals, are provided in the table 1. IRs for SAEs, SIEs and malignancies through Month 114 did not increase vs reported data through Month 105.¹ Confirmed laboratory data are provided in the table 1. No new safety risks were identified. Clinical responses were sustained from Month 1 to Month 96 (table 1).

Conclusions: In patients with RA who remained in the LTE studies, tofacitinib (5 or 10 mg BID), with or without background csDMARDs, was associated with consistent safety through Month 114 and sustained clinical efficacy through Month 96.

REFERENCE:

[1] Wollenhaupt J, et al. Arthritis Rheumatol 2016;68(suppl 10): Abstract 1647.

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by a McCluskey of CMC and funded by Pfizer Inc.

Disclosure of Interest: J. Wollenhaupt Consultant for: Pfizer Inc, Speakers bureau: Pfizer Inc, J. Silverfield Grant/research support from: Pfizer Inc, Speakers bureau: Pfizer Inc, E. B. Lee Consultant for: Pfizer Inc, K. Terry Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, K. Kwok Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, S. Strengholt Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, R. DeMasi Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, L. Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc

DOI: 10.1136/annrheumdis-2018-eular.1733

SAT0235

SUBCUTANEOUS METHOTREXATE IS SAFER AND MORE EFFECTIVE THAN ORAL METHOTREXATE ALONE AND IN COMBINATION

K. H. C. Li¹, T. Jones², M. Grove³, A. Roberts⁴, F. Birrell¹. ¹Newcastle University, Newcastle Upon Tyne, ²Sunderland University, Sunderland, ³Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, ⁴Therapy Audit Ltd, Shrewsbury, United Kingdom

Background: Methotrexate (MTX) is established as both first line therapy and combination therapy anchor drug for Rheumatoid Arthritis (RA) and other peripheral inflammatory arthritis such as Psoriatic Arthritis (PsA). There is evidence subcutaneous (sc) MTX is more effective than oral MTX, with fewer treatment failures¹⁻³, but it is not known if this holds true in routine practice and in combination.

Objectives: To show the safety & efficacy of sc MTX therapy in routine practice, compared to oral MTX, alternate monotherapy and combination therapies.

Methods: The Therapy Audit Monitoring System (TAMS, www.therapyaudit.com/tamonitor) was installed Jan 2014. Since then all new patients starting disease modifying therapy and existing patients are entered. The database was queried for diagnosis, dose and response, together with adverse events (defined as ALT>80U/l or neutrophils<2.0x10⁹/l). Statistical comparisons used the two proportion Z test, T-test or exact rate ratio test, as appropriate: significance threshold p<0.05.

Results:

Patient groups	Oral MTX only	sc MTX only	Biologics only	Conventional Combination	Biologic Combination
Total patients ever exposed – n	2093	949	570	1596	552
Patients affected by abnormal LFTs n (%)	198 (10%)	100 (10%)	47 (8%)	154 (10%)	72 (13%)
Patients affected by low neutrophils n (%)	140 (7%)	64 (7%)	66 (12%)	219 (14%)	115 (21%)
Current patients	920	425	345	921	384

8394 patients had received one or more therapies with 4109 current patients identified. Including combinations, 2650 started oral MTX (1463 current) and 1343 sc MTX (911 current). Mean (range) oral MTX dose was 17 (2.5–30) mg and sc MTX was 21 (5–40) mg (p<0.0001). 4356 adverse events were observed over follow-up in 2382 patients, with 1710 (39%) due to ALT>80U/l and 2646 (61%) to neutrophils<2.0x10⁹/l. Abnormal ALT events by drug: oral MTX 486, sc MTX 222 (p=0.92 sc vs. oral). Similarly, low neutrophil count (<2.0x10⁹/l): oral MTX 491, sc MTX 151 (p<0.00001 sc vs. oral). Rate ratios (RR) for low neutrophils for oral MTX-only vs. sc MTX-only showed highly significant differences (RR=1.40, 95% CI: 1.17–1.70; p=0.0002). 14% (1197/8294) of all patients had post-treatment DAS28 scores. Of these 59% (67/113) patients on sc MTX only, and 72% (273/377) on conventional combination achieved DAS<5.1 compared to 69% (69/98) biologic-only and 78% (102/131) biologic-combination. Sensitivity analyses examined response & toxicity by group (data not included).

Conclusions: sc MTX is safe and effective in routine practice at doses up to 40 mg. It has lower toxicity than oral MTX in monotherapy and combination, despite a higher mean dose with highly significant reduction in neutropenia rate and the same rate of liver problems compared to oral. This is the largest study of sc MTX yet reported and supports use of higher doses in selected patients and aggregation or replication of data like this may support license extension for sc MTX beyond 30 mg. If patients are usually switched to sc MTX when oral MTX is ineffective or not tolerated, many do not progress to biologic therapy: delivering good care at lower cost.

REFERENCES:

[1] Schiff MH, Jaffe JS, Freundlich B. Ann Rheum Dis 2014;73(8):1549–51.

Efficacy of baricitinib in patients with RA who failed 2 or more DMARDs

Efficacy measure, Week 24 [‡]	RA-BEACON (N=527)			RA-BUILD (N=381) [§]			RA-BEAM (N=704) [§]		
	PBO N=176	Bari 2-mg N=174	Bari 4-mg N=177	PBO N=131	Bari 2-mg N=122	Bari 4-mg N=128	PBO N=283	Bari 4-mg N=244	ADA N=177
ACR20	27	45***	46***	45	58*	71***	33	73***	68***
ACR50	13	23*	29***	25	39*	49***	17	51***	49***
ACR70	3	13***	17***	10	25**	25**	6	30*** [‡]	19***
ΔCDAI	-10.96	-15.42**	-19.41***	-14.74	-19.94***	-23.55***	-12.50	-23.98***	-21.96***
CDAI ≤10	15	23	31***	30	44*	56***	17	48***	47***
CDAI ≤2.8	3	5	9*	5	11	17**	2	14***	11***
ΔSDAI	-10.67	-15.89**	-20.20***	-14.92	-20.72***	-24.29***	-12.70	-25.56***	-23.09***
SDAI ≤11	14	22*	31***	31	48**	57***	17	50***	49***
SDAI ≤3.3	2	5	9**	4	13*	14**	2	14***	12***
DAS28-CRP≤3.2	11	20*	33***	24	46***	55***	16	53***	48***
DAS28-CRP≤2.6	6	11	22***	9	30***	37***	5	35***	31***
ΔHAQ-DI	-0.15	-0.38***	-0.43***	-0.39	-0.60**	-0.59**	-0.30	-0.71*** [‡]	-0.61***
ΔmTSS [‡]	-	-	-	0.72	0.33	0.08**	0.77	0.35*	0.26**

[2] Braun J, et al. A&R 2008;58(1):73–81.

[3] Hazlewood GS, et al. T. Ann Rheum Dis 2016;75(6):1003–08.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7556

SAT0236

LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK-1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN LABEL EXTENSION STUDY

M. C. Genovese¹, J. Kremer², S. Zhong³, A. Friedman³, ¹Stanford Univ, Palo Alto, ²Albany Medical College, Albany, ³AbbVie Inc., North Chicago, United States

Background: Upadacitinib (UPA, ABT-494) is a selective, oral JAK-1 inhibitor studied in two phase 2 randomized controlled trials (RCTs) in patients (pts) with rheumatoid arthritis (RA).

Objectives: We assessed UPA safety and efficacy in BALANCE-EXTEND, an ongoing, combined open-label extension (OLE) of the phase 2 RCTs.

Methods: Pts completing the two 12-week RCTs (in TNF-IR and (MTX-IR pts)^{1,2} could enter the OLE. Pts switched to 6 mg UPA from their RCT dose of UPA 3, 6, 12, 18 mg twice daily (BID), 24 mg once daily (QD) or Placebo. A dose increase to 12 mg BID was required for pts with <20% improvement in both SJC and TJC on 6 mg BID (at wk 6 or 12), and permitted for pts not meeting CDAI LDA. Pts without 20% improvement in SJC and TJC 6 wks after escalation, or at any 2 consecutive visits, were discontinued. The dose was decreased to 6 mg BID only in pts with a safety concern or intolerance. Pts are grouped as: Never-titrated (on 6 mg BID throughout); Titrated-up (from 6 to 12 mg BID); Titrated-up and back down (to 6 mg BID). After Jan 2017, the 6 and 12 mg BID doses were replaced by 15 and 30 mg QD extended-release equivalents currently being studied in phase 3. Data up to Jan 13 2017 are reported. Adverse events (AE) per 100 yrs of pt exposure (PY) are summarized starting from day 1 of OLE. Efficacy is assessed by ACR20/50/70 and LDA (by DAS28-CRP and CDAI), and observed data are presented up to Wk 72 of OLE due to sample size consideration.

Results: Out of 516 pts who completed the 2 RCTs, 494 entered the OLE, 493 were dosed, 328 (66.5 %) were never-titrated, 150 (30.4%) were titrated-up, and 15 (3%) were titrated-up and back down; 150 pts (30.4%) were discontinued [42 (8.5%) withdrew consent, 37 (7.5%) due to AE and 24 (4.9%) due to lack of efficacy]. Mean exposure to UPA was 525.4±221.4 days (range 1–961 days), and cumulative exposure was 725.1 PY (Table). The E/100PY for any AE in the OLE (170.5) were lower than for the RCTs in the TNF-IR (697.9, 48 PY) and MTX-IR (408.4, 54.6 PY) study populations. The E/100PY were 2.3 for serious infection, 3.7 for herpes zoster, 0.8 for malignancies excluding non-melanoma skin cancer, and 0.7 for adjudicated cardiovascular events. There were 2 deaths: one sudden death (adjudicated as undetermined or unknown cause of death) and one death due to Hodgkin's lymphoma. Changes from baseline in laboratory parameters were consistent with observations from phase 2 RCTs. For those pts completing Wk 72, efficacy was maintained in pts on 6 mg BID UPA from day 1 of OLE (never-titrated); 55% pts met ACR70 and 83% were in LDA by DAS28-CRP and CDAI based on as observed data (Table).

Summary of Adverse Events in Patients who Entered the OLE		Efficacy Measures at Week 72 in Patients who Entered the OLE, n/N (%)			
	As of Jan 13 2017 N=493, PY=725.1 Events (E/100PY) [‡]	Never-titrated	Titrated-up	Overall efficacy in OLE [‡]	
Any AE	1236 (170.5)	ACR20	208/211 (99)	76/99 (79)	287/242 (87)
Serious AE	48 (5.8)	ACR50	172/201 (75)	44/100 (44)	216/242 (90)
AE leading to discontinuation	42 (5.8)	ACR70	127/232 (55)	22/101 (22)	153/245 (64)
AE leading to death [§]	2 (0.3)	DAS28-CRP LDA	194/233 (83)	46/104 (44)	250/245 (102)
Infections	427 (58.9)	CDAI LDA	191/230 (83)	42/104 (40)	242/246 (100)
-Serious infections	17 (2.3)				
-Opportunistic infections [¶]	3 (0.4)				
-Herpes Zoster	27 (3.7)				
Anemia	19 (2.6)				
Neutropenia	13 (1.4)				
Lymphopenia	17 (2.3)				
GI perforation	0				
MMSC	5 (0.7)				
Malignancy other than MMSC	6 (0.8)				
CPK elevation	36 (5.0)				
Hepatic disorders	37 (5.1)				
VTE	5 (0.7)				
-Serious VTE	4 (0.6)				
Adjudicated cardiovascular events	5 (0.7)				
-MACE	3 (0.4)				
-Other cardiovascular events	2 (0.3)				

PT, patient years; E/100 PY, events/100 PY; AE, adverse event; MMSC, non-melanoma skin cancer; CPK, creatine phosphokinase
[‡] Multiple events occurring in the same patient are counted in the E/100PY calculation. Includes patients from Never-titrated, Titrated-up, and Titrated-up and back down groups.
[§] Sudden death, likely due to cardiac disease (undetermined or unknown cause of death); 1 death due to Hodgkin's lymphoma (non-cardiovascular death).
[¶] 1 pt with coccidioidomycosis (from an endemic area); 2 pts with oral candidiasis.
^{||} 3 pts with basal cell carcinoma; 1 pt with 2 events of squamous cell carcinoma of skin; 2 pts with breast cancer (1 pt had bilateral cancer); 2 pts with lymphoma; 1 pt with prostate cancer.
 Not symptomatic.
^{||} All isolated elevations of ALT/AST or bilirubin; no PT's Lab dates.
^{||} Serious vs non-serious VTE as determined by investigator (typically based on hospitalization).

Observed data presented for pts completing Week 72. Efficacy data reflect attention in the OLE.
[‡] Includes pts who were never-titrated, titrated-up, and titrated-up to and back down.
^{||} ACR20/50/70: 20/50/70% improvement in American College of Rheumatology criteria; DAS28-LDA, 28-point count disease activity score using C-reactive protein; CDAI, clinical disease activity index; LDA, low disease activity.

Conclusions: The safety profile of UPA remained consistent with that expected for an RA population treated with JAKi. Efficacy responses were maintained up to 72 wks in pts on 6 mg BID UPA in the OLE.

REFERENCES:

- [1] Kremer, et al. Arth & Rheum 2016;68:2867
- [2] Genovese, et al. Arth & Rheum 2016;68:2857.

Acknowledgements: AbbVie and the authors thank the patients, study sites and investigators who participated in this clinical trial. AbbVie Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version. Medical writing support was provided by Naina Barretto, PhD, of AbbVie, Inc.

Disclosure of Interest: M. Genovese Grant/research support from: AbbVie, Lilly, Astellas, Pfizer, Galapagos, Gilead, Consultant for: AbbVie, Lilly, Astellas, Pfizer, Galapagos, Gilead, J. Kremer Shareholder of: Corona, Grant/research support from: AbbVie, Lilly, Novartis, Pfizer, MedImmune, Sanofi, and Regeneron, Consultant for: AbbVie, Lilly, Novartis, Pfizer, MedImmune, Sanofi, and Regeneron, Employee of: Corona, S. Zhong Shareholder of: AbbVie, Employee of: AbbVie, A. Friedman Shareholder of: AbbVie, Employee of: AbbVie
 DOI: 10.1136/annrheumdis-2018-eular.7021